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EDUCATIONAL AIMS  
The reader will be able to: 
• Discuss the common respiratory problems encountered by indigenous children. 
• Appreciate the similarities and differences in the aetiology, associations and management of 
these common respiratory problems. 
• Understand the many facets that impact on the clinical outcomes of common respiratory 
conditions affecting indigenous children. 
• Discuss potential intervention targets that can reduce the morbidity and mortality of 
respiratory diseases in indigenous children.  
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SUMMARY  
Children in indigenous populations have substantially higher respiratory morbidity than non-
indigenous children. Indigenous children have more frequent respiratory infections that are, more 
severe and, associated with long-term sequelae. Post-infectious sequelae such as chronic 
suppurative lung disease and bronchiectasis are especially prevalent among indigenous groups and 
have lifelong impact on lung function. Also, although estimates of asthma prevalence among 
indigenous children are similar to non-indigenous groups the morbidity of asthma is higher in 
indigenous children. To reduce the morbidity of respiratory illness, best-practice medicine is 
essential in addition to improving socio-economic factors, (eg household crowding), tobacco smoke 
exposure, and access to health care and illness prevention programs that likely contribute to these 
issues. Although each indigenous group may have unique health beliefs and interfaces with modern 
health care, a culturally sensitive and community-based comprehensive care system of preventive 
and long term care can improve outcomes for all these conditions. This article focuses on common 
respiratory conditions encountered by indigenous children living in affluent countries where data is 
available.  
 
INTRODUCTION 
Globally, the disparity in health between indigenous and non-indigenous people is striking. It is 
most marked and well documented in affluent countries; Aboriginal and Torres Strait Islanders in 
Australia; Māori in New Zealand (NZ); First Nation, Inuit and Metis People in Canada; and 
American Indians and Alaska Natives (AI/AN) and Native Hawaiians in USA (here forth referred 
as indigenous).1 Indigenous populations of these countries bear a high burden of ill health from 
acute and chronic respiratory disease. In indigenous Australians, respiratory disorders are the 
second most common reason for hospitalisation.2 In indigenous populations of the USA, Canada 
and NZ, respiratory illnesses are also one of the most prevalent acute and chronic illness.3,4  
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This review focuses on the most common acute and chronic respiratory diseases in indigenous 
children living in Australia, NZ, Canada and USA. The little data on indigenous populations in 
other countries with indigenous and colonial/immigrant populations precludes meaningful 
comparison. This review does not discuss basic treatment principles as the same high quality best 
practice care is paramount in these settings and readers are referred to evidence based guidelines. 
Tobacco exposure and its effects are briefly mentioned but not discussed in depth.  
 
In these countries, the disease patterns (frequency, age distribution, severity and/or co-morbidities) 
in indigenous children have important differences compared with that of non-indigenous children. 
The severity and morbidity (eg hospitalisations) of asthma, acute and other chronic respiratory 
diseases in indigenous populations are greater compared to their non-Indigenous counterparts.5,6 
Across these countries, indigenous children share some similarities but also differences in 
respiratory diseases.1,4 For example, indigenous children with bronchiectasis living in USA, NZ and 
Australia share similarities in the frequency of household crowding, prematurity and early 
respiratory infections.4 However, there are also differences among these populations with respect to 
prevalence of wheeze, ear disease and plumbed water.4 
 
ASTHMA 
Asthma is one of the most common chronic respiratory illness in indigenous children, with 
prevalence rates of asthma of 14.3% in Canadian indigenous children aged 6-14 years,7 14.8% of 
New Zealand Māori and Pacific children aged 2-14%,5 12-23% in Australian indigenous children 
(0-17 years)8 and 13% in USA AI/AN children.9 However, the accuracy of these data is limited by 
the various definitions of asthma used. Nevertheless, asthma prevalence in indigenous children 
tends to be lower in rural regions compared to urban centres.7  
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While the prevalence of asthma in indigenous children, is similar to that of non-indigenous children, 
the associated chronic morbidity of asthma is higher in indigenous children compared to their non-
Indigenous counterparts.5,10,11 For example, the hospitalization and mortality rate for asthma is 2-3 
times higher in indigenous Australians.12 The poorer clinical outcomes have also been documented 
in indigenous children of New Zealand, Canada and USA as well as other minority groups 
globally.5,13 
 
There is little data on whether the risk factors for having asthma in indigenous children are identical 
to that in non-indigenous children. Factors that have been identified were being male, allergy, 
obesity, low birth weight, poor housing, tobacco exposure, urban residence and history of 
bronchitis.7,14 Reasons why indigenous children have poorer asthma outcomes is largely unknown 
and is likely multi-factorial. There is paucity of data that have directly compared outcomes between 
indigenous with non-indigenous children within a single setting. Through interviews, a NZ study 
found that Māori and Pacific children were more likely to receive sub-optimal asthma treatment, 
such as lower rates of the use of inhaled corticosteroids in primary care despite higher rates of 
chronic symptoms.5 An Australian study of 200 children hospitalized for asthma found that intrinsic 
biological factors are unlikely to account for the poorer asthma outcomes as there was no significant 
difference between indigenous and non-Indigenous children in the length of hospitalisation and risk 
factors (eg prematurity), other than environmental tobacco smoke (ETS) exposure.12 The 
retrospective Australian study also identified possible intervention points to improve the 
management of asthma, particularly in indigenous children. These included better identification, 
documentation and management of ETS exposure, and improvement of acute management and 
discharge planning including education and utilisation of asthma action plans.12  
 
Improvement in asthma outcomes for indigenous children will need to focus on better individual 
management and systems that support such care. Despite major advances in the understanding of 
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the pathogenesis of asthma (with relatively large amounts of research dollars), the accompanying 
benefits from public health initiatives have arguably been less than expected.13 Some have proposed 
that the priority for asthma research should be improving the use of existing treatments as evidence-
based measures to prevent (or reduce) the prevalence of asthma in children are unavailable (other 
than reducing tobacco smoke exposure).13  
 
Management of asthma  
The principles of managing asthma with respect to evidence-based use of appropriate medications 
(though a step-wise approach), use of spacers and asthma action plans to control asthma symptoms 
and reduce exacerbations are no different in indigenous populations compared to non-indigenous 
children. The key difference is the delivery of service and the framework of care (e.g. inclusion of 
indigenous healthcare workers, appropriate education resources).5,15 The problems of poor access to 
high-quality health care, affordable medications for indigenous and other minority groups in 
affluent countries has been documented.1 Indigenous children have very high rates of ETS 
exposure, a particular concern in people with asthma. Obesity and diagnostic accuracy (given high 
relatively high levels of co-morbidities such as chronic suppurative lung disease (CSLD) where 
wheeze is also common) are also of particular importance. In addition to the specific management 
issues relevant to asthma, other generic respiratory health measures (see section below) should be 
embedded in a culturally specific context  
 
ACUTE LOWER RESPIRATORY INFECTIONS (ALRIs) 
Epidemiology and context 
Globally, ALRIs including pneumonia represent the largest (18%) single cause of death in children 
aged <5-years.16 While there are substantial inter-country and inter-continental differences in the 
annual incidence of pneumonia globally (0.33 episodes per child-year in Africa, 0.05 in developed 
countries16), there is also wide intra-country variability.16 For example, in contrast to the rest of 
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Australia, ALRIs are the commonest cause of preventable deaths in infants, emergency medical 
retrievals from remote communities, and hospitalizations among indigenous children aged <5-
years.17 The incidence of hospitalized-pneumonia among infants in the Northern Territory of 
Australia (the region with the highest proportion of indigenous people) is 0.43 per child-year.18 The 
same preponderance of ALRI in indigenous children (vs non-indigenous children) is also seen in the 
USA, New Zealand and Canada.4,11,19 Hospitalisation rates for respiratory infections in AI/AN 
children were almost double that for the rest of the paediatric population (116.1 versus 63.2/1000 
respectively). Hospitalized ALRIs in Australian indigenous children are decreasing,20 but they are 
increasing among AN children (39% of all infectious disease hospitalisation  and 74% of infant 
infectious disease hospitalizations).21 In New Zealand, hospitalised ALRI rates in children aged <2 
years are 103/1,000 nationally but reach 177/1,000 in South Auckland Māori and Pacifica 
children.22 These higher rates in indigenous populations in affluent countries compared to 
developing countries is likely related to the invariably better data collection in affluent countries. 
Bronchiolitis and pneumonia account for the majority of the hospitalized ALRI burden and these 
are discussed in further details below. 
 
In addition to the high disease burden, the importance of ALRIs is also reflected in non-hospitalised 
morbidity and mortality and long term consequences especially when ALRIs are recurrent. 
Recurrent ALRIs are an independent risk factor for subsequent bronchiectasis23 and lower 
pulmonary function later in life.24 Not only are low birth weight and pre-existing small lungs 
important determinants of future lung function, but there is increasing evidence that early events in 
life are at least equally important determinants of adult pulmonary dysfunction.24,25 Early infectious 
or inflammatory insults in the first few years of life, when postnatal lung development is the most 
important, are most likely to result in long-term effects.  
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Bronchiolitis 
Bronchiolitis is the most common serious ALRI in infants. The prevalence and severity of 
bronchiolitis is greater in indigenous children compared to non-Indigenous children.6,26,27 In New 
Zealand, being Māori was as an independent risk factor for hospitalisation from RSV 
bronchiolitis.28 In contrast, a retrospective Australian study found that being indigenous was not an 
independent risk factor for RSV hospitalisation once socioeconomic risks factors were accounted 
for in their analysis.29  
 
Indigenous children with bronchiolitis have more severe disease, and poorer clinical outcomes 
including higher re-hospitalisation rates.6,27 In Alaskan children, previo s bronchiolitis is a risk 
factor for the development of chronic productive cough,30 which is the most common symptom of 
CSLD and bronchiectasis (BE). Co-existent clinical pneumonia is common in indigenous children 
with bronchiolitis and in these setting, many receive antibiotics.27 While this may be a diagnostic 
error, it is also biologically plausible. Concurrent bacterial infection are more common in those with 
severe bronchiolitis,31 and bacteria pneumonia rates may be truly higher for several reasons 
including the aspiration of nasal secretions which, in these children, contains large bacterial load.32 
This potentially overwhelms the local lung defences (mucosal and innate immunity) already 
impaired by the viral infection.33 In Australian indigenous children, bacterial (S. pneumoniae, H. 
influenzae, Moraxella catarrhalis) colonisation of the nasopharynx occurs as early 2 weeks of age 
and is heavier than in non-Indigenous children.34 Some children are susceptible to bacterial 
infections during, or shortly after, a viral respiratory tract infection and indigenous children have 
high rates of viral infections. Viral-bacterial interactions are more likely to occur when the upper 
airway respiratory epithelium is densely colonised with respiratory pathogens or with repeated 
infections.33  
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Pneumonia 
Pneumonia also has a high preponderance in indigenous children.22,35 Obtaining accurate prevalence 
figures on bacteria pneumonia is problematic as differentiating bacterial from viral or mixed-cause 
pneumonia is difficult. Even the use of WHO-defined radiological pneumonia (end-point 
consolidation (EPC)) is fraught with problems especially in the clinical context. In a cohort of 
indigenous children hospitalized with pneumonia, a paediatric pulmonologist’s blinded assessment 
of radiological pneumonia had significantly higher positive predicted value for the presence of 
crackles and elevated white cell counts when compared to WHO-EPC.36 Over a 2-year period, viral 
infection (by PCR) were positive in 90% of AN children hospitalised for ALRI.37 Among those 
with PCRs positive for influenza, parainfluenza, RSV and human metapneumovirus, 60% of 
children had radiographic evidence of parenchymal densities compatible with pneumonitis or 
pneumonia.37 The many gaps in the diagnosis and management of pneumonia in children have been 
highlighted.38  
 
In addition, indigenous children with pneumonia have associated poorer clinical outcomes and 
consequences. Indigenous Australian children hospitalised with pneumonia were 15 times more 
likely to develop bronchiectasis (OR 15.2; 95% CI 4.4, 52.7) and when pneumonia is recurrent, the 
risk increases further.23 In a cohort study, 25.6% of children hospitalised lobar pneumonia had a 
newly diagnosed and treatable chronic respiratory illness (18% CSLD) on follow-up.39 In a New 
Zealand study of predominantly (94%) Māori and Pacifica children, 74% of the 81 children 
followed at 10-14 months after hospitalization for an ALRI, had features of ongoing respiratory 
morbidity (wet cough, auscultatory chest crackles, CXR abnormalities).22 
 
Several vaccines have reduced the worldwide incidence of pneumonia. However, the benefits from 
population-based vaccination programs are not universal. Although pneumococcal vaccine (PCV)-7 
programs have significantly reduced pneumonia rates, its impact on some populations has been 
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negligible.35,40 Despite achieving high population PCV-7 vaccination coverage rates of ~90%, the 
incidence of WHO-defined radiological pneumonia in indigenous children living in the Northern 
Territory (Australia) was not significantly reduced.  Among AN children, the serotypes of 
pneumococcus causing pneumonia transitioned to those uncovered by PCV-7 with no decrease in 
the frequency of pneumococcal pneumonia related hospitalizations.35,40 The effect of PCV-13 
remains unknown. 
 
Management of ALRIs 
Outside of vaccine trials, most RCTs on pneumonia in the last 2 decades were based in resource-
poor areas41 where the risk factors, aetiologies, patient factors and settings are different to resource-
rich countries. Meta-analysis of studies have shown discrepancies in results between studies 
conducted in resource-poor vs. -rich countries.42 Those conducted in resource-poor settings have 
significantly more favourable treatment effects than in resource-rich settings.42 Extrapolating data 
from resource-poor settings to that in resource-rich countries may not be prudent. For example, the 
an Australian-based RCT evaluating the use of zinc and/or vitamin A as an adjunctive treatment of 
indigenous children hospitalized with pneumonia described likely increased harm which is in 
contrast to data in developing countries43. This likely relates to the low prevalence of micronutrient 
deficiency in Australia. Further, there is little data on long term consequences of pneumonia38 and 
indigenous children have a high risk of CSLD and bronchiectasis.4  
 
Given the link between pneumonia and bronchiectasis,23,39 as well as duration of chronic cough 
with CT bronchiectasis score and lung function decline,44 it is good clinical practice to follow up 
children 3-4 weeks afterhospitalisation. They should be screened for the presence of chronic cough 
and persistence of other respiratory symptoms and signs (wheeze and crackles in chest 
auscultation). If the cough persists, evidence-based management of chronic cough in children 
should be instituted.45  
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PROTRACTED BACTERIAL BRONCHITIS (PBB) 
PBB is a condition clinically characterised by (a) chronic (> 4 weeks) wet cough, (b) resolution of 
cough when treated with 2 weeks of appropriate antibiotics, and (c) absence of other symptoms and 
signs suggestive of other known aetiologies for cough.46 Clinicians should be cognisant that in some 
indigenous settings, parental reporting of cough is poor47 and serial observations of the child over 
multiple clinic visits are often required to determine chronicity. PBB is characterised by intense 
airway neutrophilia (40-44%) and elevated markers of neutrophilic inflammation (IL-8, MMP-9) 
accompanying the bacteria infection with upregulation of innate immunity markers.48  
 
PBB is likely linked with CSLD and bronchiectasis,49,50both of which have a high prevalence 
among Indigenous children. Early treatment of endobronchial infection can halt on-going infection 
and inflammation that predispose to chronic airway injury. Based on the increased frequency of 
chronic wet cough among different groups of indigenous children, it is likely that PBB is also more 
common in indigenous children. Reasons for this include the dense bacteria colonisation of the 
nasopharynx of indigenous children early in life,34 post-viral endobronchial bacterial infection, and 
ongoing exposure to indoor irritants such as tobacco smoke. 
 
Management of PBB 
The treatment of PBB with is based a 2-week course of antibiotics is based on common bacteria 
pathogens (S. pneumoniae, non-typable H. influenzae, M. catarrhalis) cultured from the lower 
airways.46 Children should be re-evaluated and if the cough persists or recurs, a repeat 2 week 
course of antibiotics should be prescribed. If the wet cough does not resolve, the child should be 
referred for further investigation including a chest HRCT scan. In a retrospective study of 144 
children, those whose cough failed to respond to 4-weeks of antibiotics were 21 times (95%CI 5.4-
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81.8) more likely to have bronchiectasis, especially if the child is Indigenous (OR 5.9; 95%CI 1.2-
28.5).51  
 
CHRONIC SUPPURATIVE LUNG DISEASE (CSLD) AND BRONCHIECTASIS (BE) 
We include CSLD with bronchiectasis for several reasons.52,53 These conditions overlap and 
children with CSLD experience similar clinical disease patterns as children with CT-confirmed 
BE.49 They also respond similarly to therapies used to treat children with BE.52,53 Also thirdly, 
indigenous children living in non-urban centres and children in developing countries have limited 
access to CT scanning to confirm BE and defining ‘irreversibility’ requires two CT scans, which is 
neither safe (increased radiation) nor feasible. Finally, there are limitations in the radiographic 
definitions of BE in children because HRCT definitions are derived from adult studies and are not 
necessarily equivalent to those in children. In particular, the key diagnostic criterion of 
bronchiectasis is increased bronchoarterial ratio, which is clearly influenced by age (r=0·77, 
p<0·0001).54 Also the sensitivity of determining bronchiectasis radiologically is dependent upon the 
modality used as scans obtained on a multi-detector CT scan are more sensitive than those from a 
HRCT scan.55 Thus in children, the term CSLD is used to describe a diagnosis where there are 
clinical symptoms of BE without HRCT confirmation. 
 
In the last century, CSLD/BE has declined. However in the recent two decades, CSLD/BE are 
increasingly recognised as an important contributor to chronic respiratory morbidity in both 
indigenous and non-indigenous children and adults.4 Given the requirement of a HRCT for 
diagnosis of BE, it is not surprising that there is little data on its prevalence; available figures will 
invariably be under-representative of the true prevalence. In an Australian state with the highest 
proportion of indigenous people, the incidence in indigenous infants (first year of life) is 1.18 per 
1000 child-years (95% CI, 0.60-2.16)18 and the prevalence is one in every 68 children aged <15 
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years.56 In Alaskan AI/AN children, the prevalence is one in every 63 children57 and that in Māori 
children of New Zealand is 1 in 1428.4 
 
Hospitalisation rates for CSLD/BE is increasing; the rate in Indigenous people living in 
Queensland, Australia was 2.7 times that of non-Indigenous Queenslanders in 2009.58 There is no 
data in urban Australia but among 346 children newly presenting with chronic cough to a 
respiratory service, indigenous children had a significantly higher incidence of radiological BE 
compared to non-indigenous children (29.4% vs 6.7% respectively).59 
 
Management of CSLD 
There are evidence-based guidelines for the management of CSLD/BE specific for indigenous 
people,52 which are largely the same as for non-indigenous people. Although the majority of CSLD 
and BE in indigenous children is related to previous respiratory infections, these children merit 
evaluations for serious underlying conditions such as immunodeficiencies. The principles of 
treatment include the following: (a) control of symptoms, (b) prevention and prompt treatment of 
exacerbations, (c) preservation of lung function, and (d) prevent secondary complications, such as 
haemoptysis. Treatments include combination of antibiotics, bronchodilators, airway clearance 
techniques, and regular evaluations.52 within an appropriate cultural framework. This may include 
altering the frequency of medications, such as weekly azithromycin, which we have shown is 
feasible for up to 2 years.53 
 
CONTRIBUTING FACTORS TO ALRIs AND CSLD/BE 
In indigenous settings in Australia and USA, a combination of factors may explain why the young 
children living in remote communities experience a high burden of pneumonia. Canadian,19 
Alaskan,60 and New Zealand studies have linked housing issues (e.g. overcrowding, lack of running 
water, reduced ventilation) to excess ARLIs. In an Alaskan60 study, medically high-risk status 
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(prematurity, congenital heart disease, chronic lung disease), a woodstove in the house, bottle 
feeding, and vomiting after feeding were additional risk factors for hospitalisations for ALRIs. A 
Canadian study on pneumonia and influenza identified that low education, being Aboriginal, daily 
smoking, heavy drinking, environmental factors (passive smoking, poor housing, temperature), and 
health care factors (influenza vaccination) as significantly associated with increased rates of ALRIs 
requiring medical care.61 However, in some indigenous settings housing upgrades were insufficient 
to improve health outcomes in children.62 Also, whether the lung microbiome differs (and/or 
influence disease manifestation) among indigenous and non-indigenous children within the same 
setting is unknown.  
 
These same risk factors for ALRIs pertain to CSLD-BE. A combined (Australia, NZ and Alaska) 
study of indigenous children with CSLD/BE found that the indigenous children in all regions 
experienced substantial disparities in poverty indices and risk factors (ETS exposure, low education 
levels, etc) common (similar rates) with their respective regional Indigenous populations (Table 1).4 
However, household crowding, prematurity and a high frequency and early onset of ALRIs were 
associated with development of bronchiectasis.4  
 
GENERIC APPROACH TO MANAGEMENT 
In addressing prevention of respiratory illness, social determinants of health are undeniably 
important which cannot be adequately addressed here. Major advances in indigenous child health 
will follow improvements in education and housing, and reductions in poverty, and improved 
access to high quality culturally-sensitive health care. Provision of high quality care requires the 
application of the best evidence on prevention and management of common illnesses.  
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Prevention 
The respiratory conditions discussed above share some common risk factors. Risk factors for 
development of these conditions (e.g. in utero smoke exposure, passive and active smoking, low 
birth weight, obesity) and factors associated with increased severity (e.g. poor psychosocial well-
being, passive and active smoking) are higher in indigenous people compared to their non-
indigenous counterparts. Generic and disease-specific documented risk factors are summarised in 
Tables 2 and 3.  
 
Disease specific primary prevention measures for respiratory disease are categorised into (a 
promoting normal lung development and (b removing risk factors for development of respiratory 
disease. Both share the common intervention features in Table 2 a d disease-specific interventions 
in Table 3. Strategies for secondary prevention (the early detection and treatment) and tertiary 
prevention (reduction of further complications, morbidity and mortality) are also summarised in 
Tables 2 and  3.  
 
EQUITY AND CONSEQUENCES OF POOR RESPIRATORY HEALTH IN CHILDHOOD 
In the context of indigenous health, ALRIs is an important indicator of the health disparities that 
persist between indigenous and non-Indigenous children in developed countries.63 Health is 
intertwined with every aspect of life - education, human rights, social justice, the environment, 
economy and employment. Redressing health equity through action on the social determinants of 
health for indigenous children has to occur through indigenous models of health that respect and 
understand indigenous beliefs and world iews.64,65 Racism, subtle and overt, remains a challenge in 
indigenous health care.64  
 
Addressing acute and chronic childhood respiratory disease is also important as the antecedents of 
chronic respiratory disease in adults are likely to occur in childhood. Sub-optimally treated people 
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with bronchiectasis die early and Australian Indigenous adults with BE die in their 30s and 40s.52 
Many of the common respiratory conditions discussed in this article are potentially modifiable or 
preventable through clinically based interventions. Further, chronic respiratory disease is an 
independent risk factor for cardiovascular disease, another common chronic illness leading to 
considerable mortality in indigenous adult populations.  
 
Therapeutic studies that address the severity and sequelae of common respiratory problems in 
young indigenous children are needed. These conditions are also common in resource-limited 
countries. Not surprisingly, on a global scale as well as within affluent countries, disproportionately 
fewer research dollars are spent on these common conditions. Collectively, in collaboration with 
indigenous leaders, researchers and communities, we must strive to make clinical service and 
research relevant to indigenous populations.  
 
RESEARCH DIRECTIONS 
The respiratory illnesses that have preponderance among indigenous children also affect non-
indigenous children particularly those living in developing countries. Thus, research directions on 
the many unanswered knowledge and clinical questions on asthma, pneumonia,38 bronchiolitis, 
PBB and bronchiectasis are relevant and not discussed here. Some suggested specific research 
directions are listed below but these need to occur concurrently with research (including evidence-
based policies) that addresses ways to improve the social determinants of health, education and 
training of indigenous people. 
• Determine reasons why asthma outcomes for indigenous children are poorer so as to develop 
evidence-based culture-appropriate interventions that improve asthma care and outcomes; 
• Define intervention points for the prevention of ALRIs in indigenous children, including 
reduction and delay of nasopharyngeal colonisation by respiratory pathogens in the first few 
months of life; 
Page 17 of 27
Ac
ce
pte
d M
an
us
cri
pt
17 
 
• Determine whether the airway microbiota of indigenous children with chronic suppurative lung 
disease differs from their non-indigenous counterparts;  
• Develop culturally safe environments where educators, both indigenous and non-indigenous 
work collaboratively within the framework of lung health; 
• Understand how the indigenous world view can be incorporated within a model that improves 
respiratory-specific evidence-based clinical service and practice;  
• Evaluate ways  to best provide education for parents regarding lung health that impacts care of 
children at home; 
• Reduce the incidence of low gestation age and birth weight of indigenous newborns; 
• Conduct clinical trials that prevent and/or reduce the uptake of tobacco smoking among 
indigenous school-aged children. 
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Table 1 
Demographic characteristics and known risk factors for respiratory infection in Indigenous Bronchiectasis Study children from Australia, Alaska 
United States, and New Zealand, compared with their respective Indigenous populations and general populations4 
 
                                               Australia  
Demographic Characteristics Study Local Indigenous Population National Population 
 
Household 
% % % 
Overcrowding a  84.3 58  2.6  
Caregiver Education     
High school graduate  12.4 (female) 31  83 
Bachelor’s degree 0.0 3.6 (remote)  25  
Risk Factors    
Breast feeding 86.8 84.1 (urban)  
98 (remote)  
88 
Tobacco exposure in utero 58.9 35.4  51 (Indigenous)  
15 (non-Indigenous)   
Smoke exposure (any) 84.5 98  65 (Indigenous)  
32 (general)  
Premature  37.1 14  14 (Indigenous)  
8 (general) 
Low birth weight (<2500g) 37.4 13 13.1 (Indigenous)  
6.1 (general)  
Proportion with hospitalized ARLI 87.6 49.2  4 
Age at first hospitalized pneumonia (median) 
 
6.1 months 15 months  N/A 
United States   
Demographic Characteristics Study Local Indigenous Population National Population 
Household    
Overcrowding (>1 person/room) 92.7 39 5.8 
No running water (%) 43.9 47 0.6  
Wood burning in house 47.5 37 1.7  
Educational Attainment    
High school graduate (female) 80.5 80 (both sexes)  85.6  
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Bachelor’s degree  0.0 13  27.3 
Risk Factors    
Breast feeding 63.4 79  75 
Tobacco exposure in utero 87.5 43.4 23 
Smoke exposure (any) 73.2 58  
Premature  23.3 12.8  12.2 (national)  
9.6% (Alaska) 
Low birth weight (<2500g) 12.5 5.9 
 
8.2 (national)  
5.7% (Alaska) 
Hospitalized ALRI (%) 95.1 41.2 per  1000 (Alaska Native)  
 
13.8 per 1000  
New Zealand    
Demographic Characteristics Study Indigenous Population National Population 
Household    
Overcrowded**   50.0 23 (Maori)   
43 (Pacific)  
10  
Caregiver Education    
High school graduate  50 (female) 52.0  (Pacific)  
65.4 (Maori)  
75  
Bachelor’s degree  7 (female) 8.3 (Pacific)  22   
Risk Factors    
Breast feeding  73.8 58 (Maori)  
53 (Pacific)  
65 
Tobacco exposure (any) 33.3 59.3 (Maori)  
48.1% (Pacific)  
35.3  
Premature  21.4 6.6 (Maori) 
5.6 (Pacific) 
6 
Low birth weight (<2500g) 23.1 6.8 (Maori)  
5.6% (Pacific)  
5.6 
Hospitalized ALRI  92.9 6.7/1000 (Maori)  
14.0/1000 (Pacific) 
5.0 per 1000  
Table reproduced with permission from a previous article.4 Please see original article4 for references to figures 
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Table 2 
Generic primary, secondary and tertiary prevention for asthma, acute respiratory infections and bronchiectasis 
 
PRIMARY PREVENTION 
[Normal lung development and/or 
Remove modifiable risk factors] 
SECONDARY PREVENTION 
[Early detection and appropriate 
treatment] 
TERTIARY PREVENTION 
[Reduce morbidity, mortality, secondary 
complications and adverse events from medications] 
   
Antenatal   
Avoidance of in-utero tobacco smoke 
exposure 
  
Antenatal care- prevent low birth weight    
   
Post natal   
Breast feeding Make correct diagnosis Adequate follow up 
Nutrition (avoid growth faltering and later 
obesity) 
Smoking cessation Minimisation of medications for optimal control 
Avoidance of ETS, biomass combustion, 
petrol sniffing 
Poverty alleviation  
Socio-economic factors (poverty alleviation, 
sufficient housing, etc) 
 Yearly influenza 
Vaccinations (with correct timing) Optimisation of management of other 
conditions eg malnutrition, obesity, 
anaemia, diabetes 
Avoidance of ETS, smoke, biomass combustion, air 
pollution and respiratory toxicants (e.g. cannabis, 
solvents) 
  Optimisation of management of other conditions eg 
malnutrition, anaemia, diabetes 
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Table 3: Primary, secondary and tertiary prevention specific for asthma, acute respiratory infections and bronchiectasis 
PRIMARY PREVENTION 
Normal lung development 
Remove modifiable risk factors 
SECONDARY PREVENTION 
Early detection and appropriate treatment 
TERTIARY PREVENTION 
Reduce morbidity, mortality, secondary 
complications and adverse events from medications 
   
ARIs, CSLD and bronchiectasis   
Environmental health (hygiene, sanitation, 
reduce pollution) 
Good follow up of all acute respiratory 
episodes 
Assessment for treatable causes 
Identifying predispositions to recurrent ARIs 
and CSLD (eg primary immunodeficiency 
states like hypogamma-globulinaemia 
Early diagnosis of bronchiectasis Prevent exacerbations through optimization of 
treatment such as antibiotics, corticosteroids, 
bronchodilators, mucolytics, physiotherapy and 
airway clearance methods)52 
 Early treatment of exacerbations  
   
Asthma   
 Obtain good asthma control and prevent 
exacerbations though step-up and step-
down therapies concordant with disease 
severity 
 
 Targeted asthma education and programs  
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CME SECTION 
This article has been accredited for CME learning by the European Board for Accreditation in 
Pneumology (EBAP). You can receive 1 CME credit by successfully answering these questions 
online. 
 
(A) Visit the journal CME site at http://www.prrjournal.com/ 
  
(B) Complete the answers online, and receive your final score upon completion of the test.  
 
(C) Should you successfully complete the test, you may download your accreditation certificate 
(subject to an administrative charge). 
 
 
QUESTIONS 
1. Which of the following statements is true about Indigenous children with asthma; 
(You can choose more than one item as correct)  
a. They have similar prevalence of asthma, compared to non-indigenous children. 
b. They are less likely to receive optimal treatment. 
c. They have a higher exposure to tobacco smoke. 
d. They have lower hospitalisation rates. 
e. They have better outcomes when culture-specific management approaches are used. 
 
2. Which of the following statements is true about respiratory infections among indigenous 
children? 
a. Indigenous children have higher rates of hospitalised pneumonia than that documented in 
developing countries. 
b. Prevalence of severe bronchiolitis is lower but morbidity is higher among indigenous 
children than non-indigenous children. 
c. Chronic cough is uncommon and is generally over-reported in indigenous children. 
d. Respiratory infections early in life do not impact on future lung function as adults. 
e. Indigenous children share common factors of increased severity and poorer outcomes. 
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3. Which of the following is true of indigenous children with chronic suppurative lung disease 
(CSLD)?  
a. The same approach for diagnosis and management as non-indigenous children with 
bronchiectasis should be undertaken. 
b. They do not require further investigations as recurrent pneumonia is often the cause. 
c. Poor outcomes are related to being indigenous (as opposed to sub-optimal treatment).  
d. They may be misdiagnosed as having asthma. 
e. They often have had an antecedent pneumonia.. 
 
4. Prematurity and/or low birth weight of indigenous newborns is a known risk factor for 
increased severity of which of the following conditions?  (Choose all options that are 
correct)  
a. Bronchiolitis. 
b. Bronchiectasis. 
c. Asthma. 
d. Protracted bacterial bronchitis. 
e. Recurrent pneumonia. 
 
5. Indigenous children with an episode of hospitalised pneumonia; 
a. Have the same long term prognosis as non-indigenous children. 
b. Do not require follow-up. 
c. Are at increased risk of having CSLD/bronchiectasis. 
d. Should receive a short course of antibiotics (3 days). 
e. Is often caused by environmental tobacco smoke exposure 
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